UNITED STATES SEC File Number
SECURITIES AND EXCHANGE COMMISSION 000-17788
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
(Check One) Form 10-K __ Form 20-F __ Form 11-K X Form 10-Q
__ Form N-SAR __ Form N-CSR
For Period Ended: September 30, 2010
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended:________________________
READ ATTACHED INSTRUCTION SHEET BEFORE PREPARING FORM. PLEASE PRINT OR TYPE
Nothing in the form shall be construed to imply that the Commission has
verified any information contained herein.
If the notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification relates:
--------------------------------------------------------------------------
PART I - REGISTRANT INFORMATION
Laxai Pharma, Ltd.
--------------------------------------------------------------------------
Full Name of Registrant
NexGen Biofuels, Ltd.
--------------------------------------------------------------------------
Former Name if Applicable
8905 Regents Park Drive, Suite 210
--------------------------------------------------------------------------
Address of Principal Executive Office (STREET AND NUMBER)
Tampa, Florida 33647
--------------------------------------------------------------------------
City, State and Zip Code
PART II - RULES 12b-25(b) and (c)
If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check box if appropriate)
(a) The reasons described in reasonable detail in Part III of
__ this form could not be eliminated without unreasonable
effort or expense;
(b) The subject annual report, semi-annual report, transition
X_ report on Form 10-K, Form 20-F, 11-K, Form N-SAR, or
Form N-CSR, or portion thereof, will be filed on or
before the fifteenth calendar day following the
prescribed due date; or the subject quarterly report or
transition report on Form 10-Q, or portion thereof, will
be filed on or before the fifth calendar day following
the prescribed due date; and
__ (c) The accountant's statement or other exhibit required by
Rule 12b-25(c) has been attached if applicable.
PART III - NARRATIVE
State below in reasonable detail the reasons why the Form 10-K, 20-F, 11-K, 10-Q, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach Extra Sheets if Needed)
The Company has encountered a delay in assembling the information required to be included in its Quarterly Report for the period ending September 30, 2010. The Company expects to file its September 30, 2010, Form 10-Q Quarterly Report with the U.S. Securities and Exchange Commission within 5 calendar days of the prescribed due date.
PART IV - OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
Notification.
Richard W. Jones, Esq. (770) 804-0500
------------------------ ----------- -----------------
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or
15(d) of the Securities Exchange Act of 1934 or Section 30 of the
Investment Company Act of 1940 during the preceding 12 months or
or such shorter period that the registrant was required to file
such reports been filed? If answer is no identify report(s).
X Yes __ No
(3) Is it anticipated that any significant change in results of
operations from the corresponding period for the last fiscal year
will be reflected by the earnings statements to be included in
the subject report or portion thereof? ___ Yes _X__ No
If so, attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the
reasons why a reasonable estimate of the results cannot be made.
--------------------------------------------------------------------------
LAXAI PHARMA, LTD.
------------------------------------------------------
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
LAXAI PHARMA, LTD.
Date: November 10, 2010 By: /s/ J. Ram Ajjarapu
------------------------------
J. Ram Ajjarapu, President
2
